The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about and understanding brain cancers, and the potential strategies to treat them.
COPENHAGEN, Denmark, May 29, 2025 /CNW/ -- HM King Frederik of Denmark presented neuroscientists, Professors Michelle Monje (USA) and Frank Winkler (Germany), with their Brain Prize medals and a diploma at a ceremony in Copenhagen Wednesday evening. The Brain Prize is the world's largest award for outstanding contributions to neuroscience worth EUR 1.3 million.
During the ceremony, HM The King gave a speech praising the two prize recipients for their discoveries:
"Your achievements in cancer neuroscience are truly extraordinary. You are an inspiration not only to your peers, but to generations of scientists yet to come. Thanks to your tireless efforts, there is hope that one day all types of brain cancer can be cured."
Monje and Winkler have made transformative discoveries by showing that the everyday activity that takes place in the brain drives the development of cancers within it. Recent studies further show that the influence of the nervous system is not only limited to tumours in the brain, but also tumours throughout the body.
These remarkable findings have laid the foundation for an entirely new field of research called 'Cancer Neuroscience' that represents a paradigm shift in the understanding of these cancers, and which offers vital new opportunities for treatment. New treatments are critical since cancers that arise in the brain, particularly the ones known as gliomas, are extraordinarily difficult to treat, and are the leading cause of brain tumour-related deaths in both children and adults.
The Brain Prize has been awarded every year since 2011 by the Lundbeck Foundation. The celebration takes place in Copenhagen, and this year 360 invited guests attended. Guests of honor were the prize winners and their families, as well as patron of the prize, HM The King of Denmark.
The Brain Prize 2025 is awarded to:
and
Frank Winkler, MD, Professor of Experimental Neuro-Oncology, Heidelberg University, Heidelberg University Hospital, Department of Neurology, and German Cancer Research Center
for:
Pioneering Cancer Neuroscience: disease-driving interactions between the brain and brain tumours.
MORE INFO
A portrait film about the 2025 Brain Prize winners and their science (10 min.) is available at www.thebrainprize.org alongside various additional information on the prize.
Press kit available at https://brainprize.org/media
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy Français
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. "As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred." Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. "As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally." Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. "Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health." Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of Pharmacy The School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. SOURCE GlaxoSmithKline Inc.
Cision Canada
5 hours ago
- Cision Canada
The BC Centre for Excellence in HIV/AIDS national Summit raises alarm about rising incidence of HIV in Canada and threats to global progress
Delegates call on Prime Minister to end the Canadian epidemic and lead the worldwide HIV response in light of dramatic US cuts to treatment and care VANCOUVER, BC, June 6, 2025 /CNW/ - The BC Centre for Excellence in HIV/AIDS (BC-CfE) is hosting a national Summit of medical and HIV experts to raise the alarm about the rising incidence of HIV in Canada, the immense threat that US cuts to HIV programs pose to millions at risk of disease and death globally, and the need for Canadian leadership to help prevent a resurgence in HIV/AIDS. Despite the groundbreaking work done to implement the BC-CfE's Treatment as Prevention ® (TasP ®) and HIV Pre-Exposure Prophylaxis (PrEP) programs in many jurisdictions, Canada is losing ground to HIV/AIDS across the country. The latest available government statistics for 2023 show a 35% uptick in HIV cases in Canada compared to 2022. Anecdotal discussions between BC-CfE and HIV experts across Canada indicate the situation continues to deteriorate, with HIV incidence statistics expected to be higher yet again in 2024 and in 2025. Meanwhile, the United States has substantially decreased funding to domestic programs currently supported by the US Centers for Disease Control and Prevention and Medicare, and international programs supported by PEPFAR (the US President's Emergency Plan for AIDS Relief) and USAID. UNAIDS estimates another 6.6 million new HIV infections and 4.2 million AIDS-related deaths between 2025 and 2029 if US government cuts continue. At the National TasP Summit, Dr. Julio Montaner, BC-CfE Executive Director & Physician-in-Chief, called on Prime Minister Mark Carney to take the reins and redouble efforts to end the Canadian HIV/AIDS epidemic by 2030, fully fund Highly Active Antiretroviral Therapy (HAART) and PrEP within a national pharmacare plan, and meet the UNAIDS 95-95-95 target for HIV testing, treatment and viral suppression. Meeting the UNAIDS targets * would result in a 90% reduction in HIV/AIDS-related deaths and new infections by 2030, ending the HIV/AIDS epidemic as a public health threat. "The Prime Minister has called for cost-effective, nation-building projects to improve the lives of Canadians and show leadership," said Dr. Montaner. "Redoubling efforts to defeat HIV/AIDS in Canada by 2030 fits the bill. It saves lives, prevents disease progression, improves quality of life and saves money. We have a plan. We need the Prime Minister's help to get it over the finish line." In addition, Canada must step up to better support the Global Fund to Fight AIDS, Tuberculosis and Malaria, to provide much-needed international leadership in a renewed and reinvigorated fight against HIV/AIDS. Weakening global efforts for HIV prevention, treatment, and support are already having an impact in British Columbia and throughout Canada. Domestically, HIV prevention and treatment strategies have saved countless lives and dramatically improved the lives of people living with and at-risk of HIV. However, many of Canada's new HIV cases relate to domestic and international migration, demonstrating the need for federal unity in Canada's HIV response and better support for the Global Fund. "HIV does not respect provincial, Canadian or international borders," said Summit co-chair Dr. Val Montessori, BC-CfE Director of Clinical Education. "With new HIV diagnoses rising across Canada, the need is greater than ever to implement proven HIV prevention and treatment strategies. By working together, we can strengthen the national HIV response in Canada and around the world, improve the lives of people living with HIV, and prevent new cases." *About the UNAIDS 95-95-95 Targets Based on the Treatment as Prevention strategy developed by the BC-CfE, the United Nations Joint Programme on HIV/AIDS (UNAIDS) set out ambitious targets in 2014 to end the AIDS epidemic globally by 2030. This culminated in the UN 95-95-95 Targets, which established that countries ensure 95% of people living with HIV are diagnosed, 95% of those diagnosed are on treatment, and 95% of those on treatment are virally suppressed, by the year 2025. Meeting the UN Targets would change the trajectory of the epidemic so that we would see a 90% reduction in HIV/AIDS related deaths and new HIV infections by 2030, which would herald the end of the HIV/AIDS epidemic as a public health threat. About the British Columbia Centre for Excellence in HIV/AIDS The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility – nationally and internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. The made-in-BC Treatment as Prevention ® strategy (TasP ®) pioneered by BC-CfE, and adopted by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the United Nations' 90-90-90 Target by 2020 and current UN 95-95-95 Target by 2025 – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP ® to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination ® as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, health care providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world.
Cision Canada
a day ago
- Cision Canada
Bornibus brand Tehina recalled due to Salmonella Français
OTTAWA, ON, June 5, 2025 /CNW/ - Product: Tehina Issue: Food - Microbial contamination – Salmonella Distribution: British Columbia See the affected products and product photos for this recall Media and public enquiries SOURCE Canadian Food Inspection Agency (CFIA)
